Product
Supplier
Encyclopedia
Inquiry
Tirzepatide Solid buy - large image1
Tirzepatide Solid buy - image1

Tirzepatide Solid

2006 Inquiries

Unit Price:

$2800-2900/G EXW

Get Latest Price
CAS No.:

2023788-19-2

Grade:

Industrial Grade

Content:

98%

Port:

guangzhou

Packaging:

10mg

Price valid (until):

2026-09-05

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

Ginsenoside Rb1,Ginsenoside Rg1,Ginsenoside Re,Ginsenoside CK,Ginsenoside Rg2,Ginsenoside Rg5

  • Product Description

  • Seller Information

  • Inquiry History

  • Description

    

    English Name: Tirzepatide
    CAS Number: 2023788-19-2
    Molecular Formula: C225H348N48O68
    Molecular Weight: 4813
    EINECS Number: 200-001-8
    MDL No.:

    Properties
    Storage Conditions: Store at -20°C
    Solubility: Soluble in DMSO
    Form: Solid
    Color: White to off-white
    Sequence: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-C20-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2


    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Ginsenoside Rb1,Ginsenoside Rg1,Ginsenoside Re,Ginsenoside CK,Ginsenoside Rg2,Ginsenoside Rg5

    Location:

    Chuangzhi valley,Chuangzhi Industrial Park ,Hanzhong Economic and Technological Dvelopment Zone,Hanzhong City, Shaanxi Province

    Total Annual Revenue:

    $2.5 million-$5 million

    Total Employees:

    51-100

    Year of Establishment:

    2019

  • Inquiry History
    2006 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    2023788-19-2 in unlabeled vials 10, 15 and 30 mg

    10  Feb 14, 2024
    United States

    Peptide drug GLP-1 Agonists Tirzepatide CAS 2023788-19-2 Weight loss 399 Inquiries

    10 MG Apr 3, 2024
    United States

    Tirzepatide Raw Powder Weight Loss Peptides CAS No 2023788-19-2 Tirzepatide Injection Peptides

    2 MT Dec 13, 2025
    Germany

    2023788-19-2

    1 MG Jun 18, 2026
    United States

    2023788-19-2 Retatrutide

    1 G Sep 22, 2023
    United States

    2023788-19-2 Trizepatide

    10 MT Oct 29, 2023
    United States

    Tirzepatide 2023788-19-2

    Feb 19, 2024
    United States

    Tirzepatide 2023788-19-2

    10 G Oct 31, 2023
    United States

    Trizepatide 2023788-19-2 Raw Material LY3298176 Tirzepatide powder

    Dec 2, 2025
    United States

    Fat Burning Peptides Tirzepatide 10mg/Vial 15mg/Vial Tirzepatide CAS: 2023788-19-2

    1 MT Jan 25, 2024
    United States

    Pharmacy Grade CAS 2023788-19-2 Tirzepatide 99% White powder Tirzepatide

    1 MT Oct 20, 2023
    United States

    Peptide drug GLP-1 Agonists Tirzepatide CAS 2023788-19-2 Weight loss

    2 KG Oct 20, 2023
    United States

    Pharmacy Grade CAS 2023788-19-2 Tirzepatide 99% White powder Tirzepatide

    50  Aug 17, 2023
    United States

    supply Tirzepatide Safe Material Shipping Trizepatide 2023788-19-2 Raw Tirzepatide powder

    10 MG Apr 4, 2024
    United States

    COA Offer Top quality Weight Loss Peptides Tirzepatide 10mg/vial GLP-1 2023788-19-2

    1 MT Sep 10, 2023
    Kenya

    Janoshik Test Tirzepatide 99% White powder High Quality Tirzepatide Weight loss CAS 2023788-19-2

    30 MG Dec 26, 2025
    United States

    Ex-factory price tirzepatide T30 10vials 30mg kit cas 2023788-19-2 for weight loss peptide

    10  Dec 30, 2024
    United Kingdom

    Manufacturer supply high quality hot sale lowest price Tirzepatide CAS NO,2023788-19-2 99% powder 2023788-19-2 Claire

    100 G Nov 4, 2023
    Canada

    99.9% Purity GLP-1 Injection Weight Loss Peptides Liraglutide Retatrutide Tirzepatide Semaglutide 5mg 10mg CAS 2023788-19-2

    2 MT Oct 22, 2023
    United Kingdom

    tirzepatide

    10 MG Oct 21, 2025
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.